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Hypervirulent variants of foot-and-mouth disease virus (FMDV) of serotype C arise upon serial cytolytic or
persistent infections in cell culture. A specific mutation in the internal ribosome entry site of persistent FMDV
was previously associated with enhanced translation initiation activity that could contribute to the hyperviru-
lent phenotype for BHK-21 cells. Here we report that several hypervirulent FMDV variants arising upon serial
cytolytic passage show an invariant internal ribosome entry site but have a number of mutations affecting struc-
tural and nonstructural viral proteins. The construction of chimeric type O-type C infectious transcripts has al-
lowed the mapping of a major determinant of hypervirulence to the viral capsid. Tissue culture-adapted FMDV
displayed enhanced affinity for heparin, but binding to cell surface heparan sulfate moieties was not required
for expression of the hypervirulent phenotype in Chinese hamster ovary (CHO) cells. Virulence was identical
or even higher for glycosaminoglycan-deficient CHO cells than for wild-type CHO cells. FMDV variants with
decreased affinity for heparin were selected from a high-binding parental population and analyzed. Substitu-
tions associated with decreased heparin binding were located at positions 173 of capsid protein VP3 and 144
of capsid protein VP1. These substitutions had a moderate effect on virulence for BHK-21 cells but completely
abrogated infection of CHO cells. The comparative results with several FMDV isolates show that (i) increased
affinity for heparin and alterations in cell tropism may be mediated by a number of independent sites on the
viral capsid and (ii) the same capsid modifications may have different effects on different cell types.
RNA viruses replicate as mutant swarms termed viral qua-
sispecies (16, 18, 30). The continuous generation of mutants
provides the basis for fitness gain and adaptation to changing
environments (14, 15, 19, 30). In a constant biological environ-
ment such as that provided by a clonal cell population grown
under defined culture conditions, competitive selection of viral
mutants leads to replicative optimization of the viral quasispe-
cies (4, 36, 46, 47). Work with foot-and-mouth disease virus
(FMDV), an important animal pathogen of the Picornaviridae
family, has documented the emergence of variants which are
hypervirulent for BHK-21 cells. Such variants became domi-
nant in the course of persistent infections (7–9, 39) and also
during serial cytolytic infections (3, 37, 54). The hypervirulent
FMDV variants displayed a shorter replication cycle in BHK-
21 cells and an enhanced ability to kill cells compared with the
parental viral clone (54).
The genetic alterations associated with the increase of
FMDV virulence during persistent and cytolytic viral passages
in BHK-21 cells are largely unknown. A pyrimidine transition
was identified at the base of stem 3 of the internal ribosome
entry site of the hypervirulent FMDV R100, a virus rescued
after 100 passages of carrier BHK-21 cells persistently infected
with FMDV clone C-S8c1 (9, 21). This mutation caused a 1.5-
to 5-fold increase in translation efficiency as measured with
bicistronic mRNA constructs in transfected cells (38). It was
previously proposed that such a mutation could contribute to
the increased virulence of FMDV R100 (38). The length of the
poly(C) tract located within the 59 nontranslated region of the
FMDV genome has also been suggested to be a possible vir-
ulence determinant (5, 25). However, we have not been able to
establish any correlation between the size of the poly(C) tract
of FMDV of serotype C and virulence for BHK-21 cells (21,
54).
Amino acid substitutions accumulate in the capsid of FMDV
during persistent infections in vivo (5, 24, 53) and upon per-
sistent and cytolytic passages in cell culture (8, 9, 29, 37, 54). In
the passages in cell culture, most of the replacements affected
sites exposed on the particle surface and resulted in antigenic
variation of FMDV in the absence of antibody pressure (2, 10,
13, 55). It was suggested that such substitutions may occur at
sites where they are tolerated and that they may be of a neutral
character with few phenotypic consequences (13). However,
heparan sulfate (HS) has recently been recognized as a cell
attachment molecule for FMDV (31). Sa-Carvalho et al. (51)
have reported that tissue culture adaptation of FMDV of
serotype O selects for variant viruses with positively charged
residues situated at antigenically relevant positions on capsid
proteins VP3 and VP2. These substitutions result in enhanced
binding to HS and in attenuation of the virulence of the virus
for cattle (51). In this view, integrins, in particular integrin
avb3, would be a major receptor group for FMDV (1, 23, 26,
32), but adaptation to cell culture would enhance the affinity of
the virus for HS (31, 51).
In the present study, we document that several amino acid
substitutions are fixed around the G-H loop of capsid protein
VP1 of FMDV clone C-S8c1 in the course of cytolytic infec-
tions. Such substitutions enhance the binding of the virus to
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heparin and contribute to increased virulence for BHK-21 cells
and to altered cell tropism. FMDV mutants selected for their
inability to bind heparin showed a strong reduction in virulence
for some cell types but not others.
MATERIALS AND METHODS
Cells, viruses, cDNA, and plasmids. The origin of the BHK-21 cells, proce-
dures for infections of cell monolayers, and plaque assays with FMDV have been
described previously (12, 56). Wild-type Chinese hamster ovary (CHO) cells and
the two glycosaminoglycan-deficient CHO mutants pgsD-677 (N-acetylglucos-
aminyl and glucuronosyltransferase deficient) and pgsA-745 (xylosyltransferase
deficient) were kindly provided by J. D. Esko (22, 34). Mutant pgsD-677 cells
produce no detectable HS but threefold more chondroitin sulfate than the wild-
type cells do. pgsA-745 mutant cells produce about 1% of the amount of glycos-
aminoglycan expressed by wild-type cells. CHO cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco) supplemented with nonessential
amino acids (Gibco) and 5% fetal calf serum (Gibco). For treatment with
heparinase I and III, CHO cells were grown in Ham’s F-12 medium (Gibco)
supplemented with 10% fetal calf serum.
FMDV C-S8c1 is a plaque-purified derivative of the European serotype C
natural isolate C1 Santa Pau-Spain 70 (56). FMDV C-S8c1 was used both to
establish a persistent infection in cell culture (7) and to initiate 213 serial
cytolytic infections in BHK-21 cells at a multiplicity of infection of 1 to 2 PFU per
cell (3). The FMDV population at passage 213 was used to select MARLS, a
monoclonal antibody (MAb)-resistant mutant selected with MAb SD6, which
includes an L-144 3 S substitution in VP1 (44). FMDV C-S8c1p100c1 and
C-S8c1p100c10 are two plaque-purified clones derived from FMDV C-S8c1p100
described by Martı´nez et al. (37). FMDV C-S8c1p100RGG is a C-S8c1p100-
derived MAR mutant with a D-1433 G substitution at the integrin recognition
Arg-Gly-Asp motif (37). FMDV R100 is a virus rescued after 100 passages of
carrier BHK-21 cells persistently infected with FMDV C-S8c1 (9, 21). The
proportion of MAR mutants selected with MAb SD6 was 4 3 1023 in the FMDV
C-S8c1 p100 population and 2 3 1023 in the R100 population (37).
Plasmid pFMDV-YEP-poly(C) containing the cDNA of FMDV strain O1K
under the control of the bacteriophage SP6 promoter was constructed by Zibert
et al. (60). Plasmid pO1KD3242 is a derivative of pFMDV-YEP-poly(C). For its
construction, the 3,242-bp NgoMI fragment (FMDV O1K cDNA residues 1102
to 4344) was deleted from pFMDV-YEP-poly(C) and the NgoMI restriction site
present in the vector sequence was removed by partial digestion and treatment
with mung bean nuclease (New England Biolabs). Plasmid p3,242/O1K was
constructed by subcloning the 3,242-bp NgoMI fragment of pFMDV-YEP-
poly(C) into the NgoMI site of a pGEM-5Zf(1) derivative (vector position
2695). The pGEM-5Zf(1) vector (Promega) was modified by deleting the NcoI
restriction site present in the polylinker: the vector was digested with NcoI
(vector position 37) and NotI (vector position 62), treated with mung bean
nuclease, and religated.
Single-step growth curves. Confluent BHK-21 cell monolayers (2 3 106 cells)
were inoculated with FMDV at a multiplicity of infection of 5 PFU/cell. After a
1-h absorption period at 37°C, the monolayers were extensively washed, overlaid
with 1 ml of culture medium, and further incubated at the same temperature. At
different times after infection, samples were taken for determination of infectiv-
ity (56).
Tissue culture virulence assay. Virulence for BHK-21 cells was measured by
determining the minimum number of PFU required to kill 104 BHK-21 cells in
24 h (54). For CHO cells, the time of infection was extended to 72 h.
cDNA synthesis, PCR amplification, and nucleotide sequencing. Viral RNA
extraction, cDNA synthesis, and reverse transcription-PCR amplification were
performed as previously described (20). Briefly, the supernatant of infected cell
monolayers (200 ml) was treated with 1 mg of proteinase K per ml in the presence
of 1% sodium dodecyl sulfate for 20 min at 37°C and 10 min at 45°C. Following
three phenol extractions, the RNA was recovered by two ethanol precipitations.
The oligonucleotides used for FMDV retrotranscription and amplification are
described in Table 1. PCR products were purified with the Wizard PCR Preps
DNA purification system (Promega).
Consensus nucleotide sequences were determined on PCR-amplified DNA
with either the Thermo Sequenase cycle sequencing kit (Amersham) or the fmol
method (Promega) followed by terminal deoxynucleotidyltransferase treatment
(6). The oligonucleotides used for nucleotide sequencing are described in Table
2.
Construction of full-length cDNAs of FMDV O1K encoding type C capsid
proteins. FMDV C-S8c1 and MARLS genomic residues are numbered from the
59 end, ignoring the poly(C) tract because of its variable length (3, 21). With this
numbering, the adenosine residue of the first functional AUG initiation codon is
at nucleotide 1039; the capsid-coding region spans nucleotides 1642 to 3834.
Amino acid residues have been numbered independently for each protein. cDNA
fragments encoding FMDV type C capsid proteins were obtained by reverse
transcription-PCR amplification of viral RNA with oligonucleotides described in
Table 1 (fragment F4). To perform mutagenesis, a KpnI-Hind III cDNA frag-
ment (FMDV genomic positions 1388 and 4066) was cloned in the pALTER-1
vector (Promega).
Full-length cDNAs were constructed in two steps. First, the NcoI-HindIII frag-
ment encoding C-S8c1 or MARLS capsid proteins (FMDV genomic positions
1739 and 4066) was substituted for the corresponding type O1K sequence in plas-
mid p3242/O1K. Second, full-length chimeric cDNAs, named pO1K/C-S8c1 and
pO1K/MARLS, were produced by inserting the NgoMI fragment of the corre-
sponding derivatives of p3242/O1K in the NgoMI site of plasmid pO1KD3242.
The region transferred to the O1K genetic background spans Ser-33 of VP4 to
Lys-62 of protein 2B. Since the amino acid sequence of capsid protein VP4 is
conserved between FMDV serotypes O and C, chimeric constructions encode
capsid proteins VP1 to VP4 and protease 2A of serotype C. Protein 2B is pre-
dicted to be a chimeric translation product containing the amino-terminal region
of the serotype C protein and the carboxy-terminal region of the O1K protein.
To facilitate the construction of pO1K/C-S8c1, a silent mutation, C-2826 to T,
was introduced by mutagenesis in the C-S8c1 cDNA to eliminate a NgoMI
restriction site. This silent mutation was present in the FMDV MARLS genome
(see Results). The amino acid substitution Thr-52 3 Ala identified in MARLS
protein 2B was reverted for the construction of pO1K/MARLS. To this aim, the
BstXI-ClaI fragment of the C-S8c1 pALTER-derived construct (spanning
FMDV genomic residues 3924 to 4066, followed by vector residues 56 to 479)
was substituted for the corresponding fragment of the MARLS pALTER-de-
rived construct. Nucleotide sequence analysis of the plasmidic constructions
revealed the presence of a C-23633 T mutation in the FMDV MARLS cDNA
clone compared to the MARLS virus consensus sequence. This mutation pre-
dicts an Ala-1563 Val substitution in capsid protein VP2. Mutation T-2363 was
reverted for the construction of pO1K/MARLS. To this end, the NcoI-SfiI
fragment (FMDV genomic positions 1739 to 2827), generated by restriction of
PCR-amplified cDNA of FMDV MARLS (Table 1, fragment F4), was substi-
tuted for the corresponding fragment of the p3242/O1K-derived preparation.
The resulting plasmid pO1K/MARLS includes a capsid-coding region identical
to the consensus sequence of FMDV MARLS. The construction containing the
T-2363 mutation was named pO1K/MARLST2363.
Mutagenesis. Site-directed mutagenesis was carried out with the Altered Sites
in vitro mutagenesis system kit (Promega) as specified by the manufacturer. The
single-stranded DNA template used in the mutagenesis reaction was obtained
from Escherichia coli DH5aF9 cultures harboring the pALTER-derived con-
struct. The sequence of the mutagenic oligonucleotide used was 59-CTTGGCC
GGTTTGGCCCAGTAC-39 (the mutated nucleotide is underlined).
TABLE 1. Synthetic oligonucleotides used for retrotranscription
and amplification of FMDV genomes
Fragmenta Oligonucleotide sequence (59 to 39) Orientation
F1 (1–367) TTGAAAGGGGGCGCTAGGGTC Sense
GTTAACTGAAAGGCGGGTTTCGGGTG Antisense
F2 (368–973) TAAGTTTTACCGTCTGTCCCG Sense
AAACCGAGCGCTTTTATAG Antisense
F3 (569–1643) CACGATCTAAGCAGGTTTCC Sense
CCCTTGAGCTTTCGCT Antisense
F4 (1002–4189) CGGAGGTCGGCACCTTTCCTTTAC Sense
CAAACGTGCTGTCCAGAATCTC Antisense
F5 (3988–5699) TTGGTGTCTGCTTTTGAGGAAC Sense
GCCTTCTGACCTGGAAGAGTTC Antisense
F6 (5344–7156) AAAGGCCAACACGAGGCAGC Sense
CGTCGACAATGCGAGTCTTGCCG Antisense
F7 (6610–8115) GGGTTGATCGTTGATACCAGAGA Sense
GGATTAAGGAAGCCGGGAAAGCCC Antisense
C1 (3573–4189) ACACCGTGTGTTGGCTACGGCG Sense
CAAACGTGCTGTCCAGAATCTC Antisense
C2 (2817–4189) CTTGGCCGGTTTGGCCCAGTAC Sense
CAAACGTGCTGTCCAGAATCTC Antisense
C3 (1009–3534) CGGCACCTTTCCTTTTATAACC Sense
CTTGTGGTAGGCAGTGGGATTGGTT
GTGTTGTTAAGTG
Antisense
a Amplified fragments of FMDV serotype C and chimeric type O-type C
genomes are designated by F and C, respectively; numbers in parentheses indi-
cate the oligonucleotide positions in the C-S8c1 genome, numbered as described
in Materials and Methods (20).
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In vitro transcription and cell transfection. Plasmid constructions were lin-
earized by digestion with HpaI. Transcription was performed in 40 mM HEPES-
KOH (pH 7.7)–6 mM magnesium acetate–20 mM spermidine–1 mM each nu-
cleoside triphosphate–10 mM dithiothreitol–0.1 mg of bovine serum albumin
per ml in the presence of 2 U of RNasin (Promega) per ml, 1 U of SP6 RNA
polymerase (Promega) per ml, and 5 to 50 ng of linearized plasmid per ml. The
RNA concentration was estimated by agarose gel electrophoresis and ethidium
bromide staining. BHK-21 cell monolayers at about 75% confluency were trans-
fected with 0.1 to 1 mg of RNA by using Lipofectin (38).
Heparin-Sepharose binding assay and selection of FMDV variants with de-
creased affinity for heparin. Heparin-Sepharose CL-6B and control Sepharose
CL-6B beads (Pharmacia Biotech; ligand density, ;2 mg of porcine heparin/ml
of drained gel) were resuspended as a 10% (wt/vol) slurry in phosphate-buffered
saline (PBS) containing 0.1% azide. A 500-ml volume of the viral suspension
diluted in DMEM to a final concentration of 0.2% fetal calf serum was incubated
with the equivalent of 200 ml of beads previously washed with DMEM. The virus
was allowed to bind for 1 h at room temperature with gentle rocking, and then
the titer of unbound virus was determined by a plaque assay. Binding of serial
dilutions of FMDV was analyzed to ensure that saturation of heparin binding
sites was not reached. FMDV variants with decreased affinity for heparin were
selected by using serial rounds of binding to heparin-Sepharose CL-6B beads.
Viral particles remaining in the supernatant of the viral suspension after three
rounds of incubation (30 min each) in the presence of 100 ml of heparin-
Sepharose beads were amplified in BHK-21 cells. Rounds of selection-amplifi-
cation were repeated 10 times until variants with undetectable affinity for heparin
were obtained (Fig. 1).
Heparinase treatment. CHO cells were detached from their culture surface
with PBS containing 0.5 mM EDTA, centrifuged, washed with PBS, and resus-
pended in PBSB (PBS, 0.1% bovine serum albumin) to a final concentration of
106 cells/ml. A mixture of 1 U of heparinase I (EC 4.2.2.7) and 0.5 U of hepa-
rinase III (EC 4.2.2.8) (Sigma) was added to 105 cells and incubated at 35°C for
1 h. Enzyme-treated cells were washed with PBSB and resuspended in 100 ml of
PBSB containing 0.5 mM MgCl2 and 1 mM CaCl2. Virus was added to the cells,
and the mixture was incubated for 30 min at 37°C in the presence of fresh
heparinase I and III. Extracellular virus was neutralized with 0.1 M phosphate
buffer (pH 6.0), and the cells were resuspended in DMEM containing 2% fetal
calf serum. The sensitivity of treated and untreated cells to virus infection was
estimated (i) as the minimum number of infected cells required to kill 104 wild-
type CHO cells in 72 h (cell-killing assay) and (ii) by plaque formation on a wild-
type CHO cell monolayer (plating assay).
Molecular modeling. The crystallographic coordinates of FMDV C-S8c1 (33)
have been used as starting model. The conformation of the G-H loop of VP1 and
its position in the viral capsid has been taken from the structure of the complex
with MAb SD6 (27, 57). The substitutions found in the capsid of variant FMDVs
have been modeled with the program TURBO (49) by placing the side chain
atoms of the substituted amino acids in their standard conformations. The struc-
ture was then optimized by removing the close contacts with the same program.
RESULTS
Multiply passaged FMDV MARLS displays hypervirulence
for BHK-21 cells. Prolonged serial cytolytic passage of FMDV
C-S8c1 in BHK-21 cells resulted in selection of hypervirulent
variants together with defective FMDV genomes lacking part
of the leader (L) protease gene (3). A MAb-resistant mutant
isolated from passage 213 (MARLS) (Fig. 1) was compared
with the parental C-S8c1 virus with regard to replication kine-
tics (Fig. 2A) and virulence for BHK-21 cells (Table 3). In the
standard infection protocol, complete cytopathic effect was
observed 4 to 6 h after infection of BHK-21 cells with FMDV
MARLS and 16 to 20 h after infection with C-S8c1. Also, the
maximum virus titer observed was 10-fold higher for MARLS
than for C-S8c1. These titers correspond to an average infec-
tious-virus production of 200 and 20 PFU/cell, respectively. It
is remarkable that the ability to kill BHK-21 cells in a standard
virulence assay was about 103-fold greater for MARLS than for
the parental FMDV C-S8c1 (Table 3).
Analysis of the MARLS virus genome. The nucleotide se-
quence of the entire MARLS genome was compared with that
FIG. 1. Passage history of serotype C FMDV variants analyzed in this study.
Plaque-purified FMDV C-S8c1 (n) passaged once cytolytically in BHK-21 cells
(E) was further propagated in BHK-21 cells either in cytolytic or in persistent
infections. C-S8c1-derived populations p100 and p213 were obtained after 100
and 213 serial cytolytic passages, respectively. Clones c1 and c10 were isolated
from C-S8c1 p100 (37). RGG and MARLS are two mutants resistant to MAb
SD6 (3, 37). FMDV MARLS was subjected to 10 rounds of selection and
amplification (bE) with heparin-Sepharose binding and infection of BHK-21
cells, to eliminate viruses with high affinity for heparin. This led to the isolation
of clones MARLS/hs2 c1, c2, c3, and c4 (bottom right). Procedures for cytolytic
infections and isolation of virus from single plaques are described in Materials
and Methods. Persistent FMDV infections and the R100 population were de-
scribed previously (8, 9, 21).
TABLE 2. Synthetic oligonucleotides used for nucleotide
sequence determination of FMDV genomes
Oligonucleotide sequence (59 to 39) Positiona Orientation
TTGAAAGGGGGCGCTAGGGTC 1 Sense
CAGCGCTAACAACCAAGTAG 236 Antisense
GTTAACTGAAAGGCGGGTTTCGGGTG 367 Antisense
TAAGTTTTACCGTCTGTCCCG 368 Sense
CACGATCTAAGCAGGTTTCC 569 Sense
TGTCAGTTGGGGAAACCTGC 599 Antisense
CTTGGTAACAAGGACCCAC 750 Sense
CGGAGGTCGGCACCTTTCCTTTAC 1002 Sense
GCCTTCCACCCTTCATTGAGTGGC 1619 Antisense
AACCAGTCGTTGGTCTGG 1844 Antisense
CAACCTTGTGCATGTGTCC 2140 Antisense
GGGTTGATGAACTGGTGGGG 2345 Antisense
CAGTTGTCACCATGTTGCC 2602 Antisense
CTTGGCCGGTTTGGCCCAGTAC 2817 Sense
GTACTGTGTGTAGTACTGCGC 2850 Antisense
GTTTCAGCCTCGTGGGACGC 3077 Antisense
CTTGTGGTAGGCAGTGGGATTGG
TTGTGTTGTTAAGTG
3534 Antisense
ACACCGTGTGTTGGCTACGGCG 3573 Sense
CTGCACCAAAGTTGAACGAT 3697 Antisense
GAGAAGAAGAAGGGCCCAGGGTT
GGACT
3896 Antisense
CAAACGTGCTGTCCAGAATCTC 4189 Antisense
GAAGACCTTGAGAGAGCAGAG 4338 Sense
CTCTTCTGAGGCGATCCATGC 4158 Antisense
CGCTCACGTCGATGTCAAAGTG 5047 Antisense
AAAGGCCAACACGAGGCAGC 5363 Sense
GAGTCGTGTACCATGCCCTC 5396 Antisense
GAACTCTTCCAGGTCAGAAGGC 5677 Sense
GTAAGTGGTGCCCCACCGACCGAC 5971 Sense
CATGACCATCTTTTGCAGGTCAG 6009 Antisense
CCCCCGTCGTTGGCGTGATTAAC 6308 Sense
GGGTTGATCGTTGATACCAGAGA 6610 Sense
ACCACTGCAGCGATGCCATGAAC 7349 Sense
GGCATCGCTGCAGTGGTTTGC 7365 Antisense
CTTGCCACCACGATGTCGTC 7640 Antisense
GGATTAAGGAAGCCGGGAAAGCCC 8115 Antisense
a Positions refer to the C-S8c1 genomic residues, numbered as described in
Materials and Methods (20).
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of C-S8c1 (Table 4). Interestingly, mutations at the 59 non-
translated region were located outside the internal ribosome
entry site element, indicating that the hypervirulence pheno-
type of FMDV does not require substitutions at this regulatory
domain. The amino acid substitutions at the nonstructural pro-
teins 2C, 3C, and 3D affected regions which are considerably
variable when different picornaviruses are compared (61; cur-
rent alignments in GenBank). Only the Glu-1653 Gly substi-
tution in the L protease affected a position which is conserved
among the sequenced FMDVs of serotypes A, C, O, and
SAT-2 (50). Amino acids substituted in the capsid were located
at exposed sites, as defined by accessibility to a probe with a
radius of 2 Å (33, 43). Antigenic site A was affected by the VP1
Leu-144 3 Ser replacement (the substitution responsible of
the MAR phenotype), and the His-1973 Arg and Pro-2003
Gln substitutions were located in antigenic site C (33, 41) (Ta-
ble 4).
RNAs derived from chimeric O1K full-length cDNAs encod-
ing type C capsid proteins are infectious. To investigate wheth-
er the capsid of FMDV could influence its virulence for BHK-
21 cells, it was important to transfer the capsid-coding regions
of C-S8c1 and MARLS into the same viral genetic background.
Entire infectious cDNA clones of FMDV serotype C have not
been described. In contrast, complete infectious cDNA clones
have been obtained for serotypes O1K and A12 (48, 60). There-
fore, to analyze the possible implication of type C structural
proteins in hypervirulence for BHK-21 cells, chimeric type O-
type C FMDVs including the capsid of serotype C were con-
structed. The capsid-coding regions located between the NcoI
(position 1739) and HindIII (position 4066) restriction sites of
FMDV C-S8c1 and MARLS cDNAs were substituted for the
corresponding sequence in the type O1K full-length cDNA
(60), as detailed in Materials and Methods (Fig. 3). BHK-21
cells were transfected with the transcription products of each
of the chimeric cDNAs (Fig. 3). RNA derived from the FMDV
O1K cDNA clone [pFMDV-YEP-poly(C)] was used as a con-
trol. A complete cytopathic effect was observed at 20 to 24 h post-
transfection in BHK-21 monolayers transfected with RNA tran-
FIG. 2. Comparison of the virus production upon infection of BHK-21 cell monolayers with (A) FMDV C-S8c1 and the MARLS variant (A) and chimeric FMDVs
O1K/C-S8c1, O1K/MARLS, and O1K/MARLST2363, including the capsid of C-S8c1 or its hypervirulent derivatives (described in Materials and Methods) (B). In all
cases, BHK-21 cells were infected at a multiplicity of infection of 5 PFU per cell. Virus titers at different times after infection were determined by plaque assays on
BHK-21 cells monolayers (12). Each value represents the mean and standard deviation from triplicate assays.
TABLE 3. Phenotypic traits of FMDV variants with different
passage histories in BHK-21 cell cultures
FMDV
straina
Binding to
heparinb
Virulence forc:
BHK-21
cells
CHO cells
Wild type pgsA-745 pgsD-677
C-S8c1 2 105 2 2 2
O1K 11 103 104 2 2
MARLS 111 102 104 102 104
MARLS/hs2c1 2 103 2 2 2
MARLS/hs2c2 2 103 2 2 2
MARLS/hs2c3 2 102 2 2 2
MARLS/hs2c4 2 103 2 2 2
O1K/C-S8c1 2 104 2 2 2
O1K/MARLS 111 102 102 10 102
O1K/MARLST2363 11 10
2 103 10 102
C-S8c1p100c1 11 102 105 103 105
C-S8c1p100c10 11 102 105 103 105
C-S8c1p100RGG 1 103 105 104 105
R100 11 103 2 2 2
a The origin of each FMDV strain is shown in Fig. 1 and is described in Ma-
terials and Methods. FMDV C-S8c1p100c1 and C-S8c1p100c10 are two plaque-
purified clones derived from C-S8c1 after 100 serial passages in BHK-21 cells;
C-S8c1p100RGG is a C-S8c1p100-derived MAR mutant with a substitution at
the Arg-Gly-Asp motif; FMDV R100 was rescued after 100 passages of carrier
BHK-21 cells persistently infected with C-S8c1. FMDV O1K was obtained by
transfection of BHK-21 cells with infectious O1K transcripts derived from plas-
mid pFMDV-YEP-poly(C) (60). FMDV O1K used was at passage 1.
b Binding to heparin was estimated as the ratio of PFU remaining in the
supernatant of a viral suspension after incubation with control beads (without
heparin) relative to heparin-Sepharose beads. Binding was classified as follows:
1, 2 , ratio , 50, where 2 is the limit of positive detection; 11, 50 # ratio ,
5 3 102; 111, 5 3 102 # ratio , 5 3 103; 2, no detectable binding (ratio, ;1).
Further details on heparin binding assays are given in Materials and Methods.
c Minimum number of PFU required for complete cell killing of 104 BHK-21
cells in 24 h or 104 CHO cells in 72 h. Thus, a large number corresponds to low
virulence; 2, no cytopathic effect in the presence of the following PFU for the
different FMDVs: 1 3 106 (C-S8c1), 2 3 105 (O1K), 7 3 106 (MARLS/hs2 c1 to
c4), 2 3 106 (O1K/C-S8c1), 6 3 105 (R100). Each value represents the average
of triplicate determinations.
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scripts from pO1K/MARLS or pO1K/MARLST2363. Viral titers
in the supernatant of transfected cells ranged from 2 3 107 to
4 3 107 PFU/ml. In contrast, transcripts from pO1K/C-S8c1 or
pFMDV-YEP-poly(C) resulted in cytopathologic changes at
about 48 h posttransfection. Viral titers ranged from 3 3 105 to
4 3 106 PFU/ml. No cytopathic effect was observed in parallel
transfections carried out in the absence of RNA. The chimeric
virus progeny was neutralized by serotype C-specific MAbs
directed to antigenic site D (33).
RNA from chimeric viruses resulting from one round of rep-
lication after transfection were copied into cDNA and ampli-
fied by PCR, and the regions encoding the capsid proteins
and neighboring viral products were sequenced. Nucleotide
sequences diagnostic of serotype O FMDV were found at the
regions around those encoding the capsid. Apart from the si-
lent mutation T-2826 introduced by mutagenesis (see Materi-
als and Methods), the nucleotide sequence encoding the capsid
proteins of the O1K/C-S8c1 chimera was identical to the cor-
responding sequence of C-S8c1. Mutations present in the cap-
sid-coding regions of MARLS were found in the viral progeny
derived from the O1K/MARLS and O1K/MARLST2363 chime-
ras. As expected, the O1K/MARLST2363 genome included a
thymidine residue at position 2363. The virus production of the
chimeric O1K/MARLS viruses was about 10-fold lower than
that of the authentic MARLS. The times at which maximum
cytopathic effect and maximum virus titers were reached were
shorter for the MARLS-containing than for the C-S8c1-capsid
containing chimeras (Fig. 2B). The results indicate that type C
structural proteins are expressed in a functional form in the
genetic context of a serotype O FMDV and are able to encap-
sidate chimeric type O-type C FMDV genomes. The chimeric
viruses manifest a different replication kinetics, which is de-
pendent on the nature of the capsid-coding regions.
Phenotypic characterization of FMDV chimeric progeny and
comparative analysis of additional mutant FMDVs. A number
of mutants of FMDV with various amino acid substitutions in
their capsid proteins have been isolated in our laboratory over
the last decade (17, 37) (Fig. 1). They differ in the number of
passages in BHK-21 cells and thus in the degree of adaptation
FIG. 3. Schematic representation of the capsid coding region of FMDV O1K
and of C-S8c1 and its variant derivatives, as inserted in the parental type O1 plas-
mid pFMDV-YEP-poly(C) (60). Type C genomic regions are represented by
open boxes. NgoMI restriction sites and their numbering refer to FMDV O1K
cDNA (60). NcoI and Hind III sites and their numbering refer to the C-S8c1 ge-
nome (20). Amino acid residues differing in the compared chimeric genomes are
indicated. The vertical numbers at the bottom refer to the corresponding posi-
tions in each protein. Infectious transcripts were produced with plasmid
pFMDV-YEP-poly(C), and derived constructs encoding the cDNA of FMDV
O1K or type O-type C chimeras under the control of the SP6 promoter. The
amino acid sequence of protein VP4 is conserved among the FMDVs of sero-
types O and C analyzed here. Procedures for the construction of chimeric viruses
and confirmatory sequence analysis of chimeric progeny are described in Mate-
rials and Methods. O1K/MARLS includes a capsid-coding region identical to the
consensus sequence of FMDV MARLS. T-2363 indicates an Ala-156 3 Val
mutation in protein VP2 that was accidentally selected during the cloning pro-
cedure. Infectious transcripts were produced with plasmid pFMDV-YEP-poly(C)
and derived constructs encoding the cDNA of FMDV O1K or type O-type C
chimeras under the control of the SP6 promoter. The amino acid sequence
of protein VP4 is conserved among the FMDVs of serotypes O and C analyzed
here. Procedures for the construction of chimeric viruses and confirmatory se-
quence analysis of chimeric progeny are described in Materials and Methods.
TABLE 4. Mutations and corresponding amino acid substitutions
found in the FMDV MARLS genome as
compared to FMDV C-S8c1
Genomic
region Mutation
a Amino acid
substitutionb
Secondary
structurec
59 nontranslated
region
C-247 3 T NCR
C-338 3 T NCR
G-476 3 A NCR
T-518 3 C NCR
L protease G-1091 3 T Arg-18 3 Ile
C-1105 3 T Pro-23 3 Ser
A-1532 3 G Glu-165 3 Gly
VP2 G-2285 3 A Gly-130 3 Asp E-F loop
VP3 T-2622 3 C 2
C-2624 3 T Ala-25 3 Val N terminus
C-2826 3 T 2
G-3067 3 A Glu-173 3 Lys G-H loop
T-3082 3 A Cys-178 3 Ser G-H loop
C-3202 3 A Gln-218 3 Lys C terminus
VP1 A-3328 3 G Lys-41 3 Glu bB strand
C-3423 3 T 2
T-3638 3 C Leu-144 3 Ser G-H loop, anti-
genic site A
A-3797 3 G His-197 3 Arg C terminus, anti-
genic site C
C-3806 3 A Pro-200 3 Gln C terminus, anti-
genic site C
2B A-4036 3 G Thr-52 3 Ala
2C G-4583 3 A Ser-80 3 Asn
A-5110 3 G Thr-256 3 Ala
G-5133 3 C Gln-263 3 His
A-5191 3 G Met-283 3 Val
3A A-5364 3 C 2
3C T-6225 3 C 2
A-6295 3 C Met-109 3 Leu
3D T-6744 3 C 2
A-7305 3 C Gln-232 3 His
G-7554 3 T 2
T-7564 3 C 2
T-7932 3 C 2
a Procedures for sequencing the entire FMDV genome are described in Ma-
terials and Methods. The first letter corresponds to the nucleotide found in the
parental FMDV C-S8c1, and the number gives the nucleotide position in the
C-S8c1 genome, according to reference 20. Mutation T-3638 3 C (Leu-144 3
Ser) is responsible for resistance to neutralization by MAb SD6 (37). Except for
this mutation, the capsid coding sequence of C-S8c1 p213 is indistinguishable
from that of MARLS.
b The first amino acid is the one found in C-S8c1; amino acid residues are
numbered independently for each protein. NCR, noncoding region; 2, silent
mutation.
c Secondary-structure assignments are as described in references 33 and 43.
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to this cell line, as evidenced by an increase in relative fitness
values with passage number (28, 36). Since it has been sug-
gested that an increase in heparin binding may be associated
with adaptation of FMDV of serotype O to cell culture (31,
51), it was of interest to analyze our collection of mutant
FMDVs as well as the chimeric type O-type C viruses with re-
gard to binding to heparin and its possible association with
virulence for cells in culture. The results (Table 3) show that all
variants derived from passage of C-S8c1 in BHK-21 cells dis-
played enhanced virulence for this cell line and acquired the
ability to bind heparin, albeit to different extents. Likewise, the
O1K/MARLS chimeras were also able to bind heparin, in con-
trast to FMDV C-S8c1 and to the O1K/C-S8c1 chimera (Table
3). The O1K/MARLS chimeras were 100-fold more virulent
for BHK-21 cells than the O1K/C-S8c1 chimera, in agreement
with the results of the single-step growth experiments (Fig. 2B)
and reflecting the origin of the capsid proteins (Table 3). The
conclusions were also supported by the results of heparin in-
hibition assays (Fig. 4). Both the infectivity and virulence for
BHK-21 cells of FMDV O1K, p100c10, p100RGG, and MARLS,
but not of C-S8c1 or MARLS/hs-c1, were reduced by soluble
heparin (Fig. 4). Interestingly, the infectivity of R100 was not
affected by heparin despite its positive heparin binding (com-
pare Fig. 4 and Table 3).
FIG. 4. The effect of soluble heparin on the infectivity of FMDV. Mixtures of the indicated FMDV (50 to 300 PFU) and the amount of heparin (Sigma; from bovine
lung, sodium salt) were incubated in DMEM for 10 min at 25°C. Then the mixtures were applied to confluent monolayers of either BHK-21, wild-type CHO (WT-CHO),
or pgsA-745 CHO cells. After an adsorption period of 1 h at 37°C, the monolayers were washed and overlaid with DMEM containing 1% fetal calf serum and 0.5%
agar. Plaques were visualized by staining with crystal violet. Plaque formation by mutant p100RGG required the presence of DEAE-dextran (0.08 mg/ml) in the
semisolid medium. Percent plaque reduction was calculated relative to parallel assays with each virus and cell type in the absence of heparin. In addition, virulence
assays were performed, as described in Materials and Methods, in the absence or presence of heparin (1 mg/ml) in the virus to be tested. Virulence values are given
in parentheses (absence or presence of heparin) and are defined as indicated in Materials and Methods. Some viruses were tested only in BHK-21 cells because they
do not infect CHO cells under the assay conditions used (see the text and Table 3).
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To further investigate the involvement of GAG in the ac-
quisition of virulence in tissue culture, wild-type CHO cells and
mutant CHO cell lines deficient in GAG biosynthesis (22, 34)
(described in Materials and Methods) were tested in the viru-
lence assay (Table 3). The chimeras containing the MARLS
capsid were able to replicate in both wild-type CHO cells and
GAG-deficient CHO cell lines pgsA-745 and pgsD-677. Rep-
lication of MARLS in CHO cells did not entail selection of a
variant with substitutions in the capsid, as documented by se-
quencing of the capsid-coding region of progeny from an in-
fection of wild-type CHO cells and mutant pgsA-745 cells with
MARLS. The deduced amino acid sequences of the capsid
proteins of the parental and progeny viruses were identical.
The virulence of all these viruses for pgsA-745 cells was 10- to
100-fold higher than for wild-type and mutant pgsD-677 CHO
cells (Table 3). In parallel assays, FMDV O1K was able to kill
wild-type CHO cells but not mutant CHO cells, as previously
described for other O1 isolates (31, 51) (Table 3). All FMDV
C-S8c1p100-derived viruses (Fig. 1) (37) were able to infect
wild-type and mutant CHO cells (Table 3). Only the FMDV
mutant p100RGG showed a slightly diminished ability to bind
heparin and a somewhat lower virulence for BHK-21 and pgsA-
745 CHO cells (Table 3). Finally, the persistent FMDV R100
was also tested. This population acquired high virulence for
BHK-21 cells as a result of coevolution with the host cells (8,
9, 52) (Fig. 1). Interestingly, R100 showed moderate heparin
binding and was not capable of replicating in CHO cells (Table
3) (see Discussion). For viruses that infect wild-type CHO
cells, heparin caused a strong inhibition of both infectivity and
virulence (Fig. 4). The inhibition was 10- to 30-fold lower in
parallel assays employing with pgsA-745 cells (Fig. 4).
To further document that HS is not required for infection of
CHO cells by FMDV MARLS, wild-type and GAG-deficient
CHO cells were treated with mixtures of heparinase I and III,
as described in Materials and Methods. No reduction of the
infectivity of MARLS was observed after heparinase treatment
of pgsA-745 or pgsD-677 CHO cells; only a twofold reduction
was measured upon heparinase treatment of wild-type CHO
cells. In parallel treatments of wild-type CHO cells, a reduction
of 5-fold (plating assay) and 25-fold (cell killing assay) in the
infectivity and 25-fold in the virulence of FMDV O1K was
observed. Furthermore, in contrast to the FMDVs of serotype
C tested, plaque development of FMDV O1K on wild-type
CHO cell monolayers in semisolid agar medium (12) was com-
pletely inhibited in the presence of DEAE-dextran (0.08 mg/
ml).
These results suggest that the affinity for heparin is a phe-
notypic property of tissue culture-adapted FMDV of serotype
C and that infection of CHO cells by FMDV MARLS and
C-S8c1p100-derived viruses does not require the presence of
cell surface HS moieties.
Selection and characterization of FMDV MARLS variants
with decreased affinity for heparin. Variants with decreased
affinity for heparin were selected from the MARLS population
by using heparin-Sepharose beads, as described in Materials
and Methods. After 10 rounds of selection for negative bind-
ing, a total reversion of the heparin-binding phenotype was
observed. Four FMDV clones were isolated from the subpopu-
lation MARLS/hs2, which were unable to bind heparin (Fig.
1). The four individual clones (c1, c2, c3, and c4) did not show
detectable binding to heparin (Table 3). In addition, heparin
inhibition was tested with clone c1, with negative results, as
expected (Fig. 4). Sequencing of the capsid-coding region re-
vealed that clones c1, c2, c3, and c4 had the same two amino
acid replacements on the capsid: Lys-173 3 Met in VP3 and
Ser-1443 Leu in VP1. The latter replacement represents the
reversion of the substitution responsible for resistance to MAb
SD6. The presence of an uncharged Met residue in position
173 of VP3 in MARLS/hs2 and of Glu in the corresponding
position of C-S8c1 suggests that the positively charged Lys-173
in VP3 is essential for binding to heparin and for infection of
CHO cells (compare Tables 3 and 5). The results provide
evidence that VP1 position 144 may also play a role in heparin
binding and infectivity for CHO cells (see Discussion).
All MARLS/hs2 clones tested lost the ability to infect CHO
cells, and three of four clones displayed a virulence for BHK-
21 cells which was 10-fold lower than that of MARLS but still
102-fold higher than that of the parental C-S8c1 (Table 3). This
suggests that the BHK-21 cell-specific virulent phenotype dis-
played by FMDV MARLS does not have identical determi-
nants to those of the virulent phenotype for CHO cells.
Location of the amino acid residues involved in heparin bind-
ing and cell tropism. The atomic coordinates of FMDV C-S8c1
obtained by X-ray crystallography (33, 57) were used (i) to mod-
el the amino acid substitutions found in the capsid of FMDV
MARLS and R100 on the capsid of C-S8c1 and (ii) to position
the residues responsible for heparin binding on the three-
dimensional structure of the virion (Fig. 5). With the exception
of the VP1 residue Glu-46, all mutations fixed in the capsid of
FMDV C-S8c1p100c10 upon serial passages in BHK-21 cells
were maintained in the MARLS mutant (Table 5). Of the five
conserved replacements, four mutations (Glu-173 3 Lys and
Gln-218 3 Lys in VP3, Lys-41 3 Glu and His-197 3 Arg in
VP1) were clustered around the position occupied by the G-H
loop of VP1 (27, 37). In particular, a 4.7-Å minimal side chain-
TABLE 5. Amino acid substitutions found in capsid proteins
of FMDV variants with different passage histories
in BHK-21 cell culturesa
Viral
protein Position
b
Amino acid in:
C-S8c1 C-S8c1p100c10 MARLS R100
VP2 130 Gly 2c Asp 2
192 Ala 2 2 Thr
193 Gly 2 2 Ser
VP3 7 Cys 2 2 Val
9 Asp 2 2 Ala
13 Asn 2 2 His
14 Met 2 2 Leu
25 Ala Val Val 2
173 Glu Lys Lys 2
178 Cys 2 Ser 2
194 Asp 2 2 2
218 Gln Lys Lys 2
VP1 41 Lys Glu Glu 2
46 Asp Glu 2 2
83 Thr 2 2 Ala
144 Leu 2 Ser 2
145 Ala 2 2 2
148 Thr 2 2 Lys
164 Val 2 2 2
194 Gly 2 2 Asp
197 His Arg Arg 2
200 Pro 2 Gln 2
a All variant FMDVs compared are derived from clone C-S8c1, as depicted in
Fig. 1 and as described in Materials and Methods.
b Amino acid residues are numbered independently for each protein, and the
positions refer to clone C-S8c1 (20). No mutations were found in the VP4 coding
region.
c 2, no substitution found in the virus.
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side chain distance was measured between residues R-141 (Nε)
of the VP1 G-H loop and K-173 (Cd) of VP3, which is involved
in heparin binding and cell tropism modification. Additional
amino acid substitutions found in the capsid of FMDV MARLS
(VP2 Gly-1303 Asp, VP3 Cys-1783 Ser, and VP1 Pro-2003
Gln) (Table 5) also mapped close to the loop (Fig. 5). The SD6
MAR mutation Leu-144 3 Ser is located at antigenic site A
within G-H the loop of VP1 (Fig. 5).
Mutations found in the capsid of FMDV R100 differed dras-
tically from those of FMDV MARLS and C-S8c1p100c10 (Ta-
ble 5). Whereas capsid alterations accumulated around the
VP1 G-H loop in the course of cytolytic infections, evolution in
persistently infected carrier cells led to substitutions around
the pore located at the fivefold axis of symmetry (Fig. 5). In
addition, the Thr-1483 Lys and Gly-1943 Asp substitutions
in VP1 and the Ala-192 3 Thr and Gly-193 3 Ser substitu-
tions in VP2 are fixed in R100. The results suggest that mul-
tiple sites which are distant on the capsid of FMDV of serotype
C can modulate the affinity of FMDV for heparin.
DISCUSSION
Viral quasispecies replicating under conditions which ensure
competitive rating of genomes from the mutant spectra move
toward high-fitness peaks (15). For viruses replicating in cell
culture under a constant environment, an increased ability to
kill cells and produce progeny will be strongly selected (54).
This ability may be associated with optimization of any limiting
step in the viral replication cycle: recognition of the cell recep-
tor, virus entry, uncoating, expression of viral genes, genome
replication, particle assembly, or release of virus particles from
cells.
Cell receptor recognition is an essential step in any infection
process, and it is currently recognized that many viruses are
capable of using several cellular receptors and coreceptors.
This may contribute to an expanded host range and to an
increased probability of virus survival. For FMDV, integrins, in
particular avb3, were the first receptors to be identified (1, 23,
32, 40). Recently, Jackson et al. (31) found that, in common
with other natural ligands of some integrins, binding to the
ubiquitous cell surface GAG was required for efficient infec-
tion of cultured cells by FMDV of serotype O. These results
were confirmed and extended by Sa-Carvalho et al. (51) work-
ing with chimeric type A-type O FMDVs. Their results showed
that tissue culture-adapted variants included positively charged
residues exposed in capsid proteins VP2 and VP3 that medi-
ated heparin binding and the ability to infect CHO cells. These
observations revealed that entry of FMDV type O into cells is
a complex process and that HS may mediate the first contact
between the cell and the virus in tissue culture (31, 51).
In the present study, we have analyzed a collection of FMDV
serotype C variants which were obtained as a result of either
persistent or serial cytolytic infections of clone C-S8c1 (56) in
BHK-21 cell cultures (Fig. 1). Our initial aim was to map the
hypervirulent phenotype for BHK-21 cells, first described for
persistent virus R100 (8, 9) and later found to be a trait also
selected upon serial cytolytic passage of the same viral clone (3,
54). With the construction of chimeric type O-type C viruses
(Fig. 3), it has been possible to assign major determinants of
hypervirulence for BHK-21 cells to the viral capsid. Indeed,
several chimeras including the capsid of the tissue culture-
adapted MARLS variant were 102-fold more virulent for BHK-
21 cells than were the same constructs including the capsid of
the parental clone C-S8c1 (Fig. 2; Table 3).
The use of several FMDV mutants, all derived from clone
C-S8c1 but with different, albeit controlled evolutionary histo-
ries (Fig. 1), has established that the increase in virulence for
BHK-21 cells paralleled an enhanced ability to bind heparin.
For all FMDV C-S8c1-derived variants selected upon cyto-
lytic passages in BHK-21 cells (MARLS, chimeras with the
FIG. 5. Locations of the amino acid substitutions found in FMDV MARLS (A) and FMDV R100 (B) on a ribbon protein diagram of a crystallographic protomer
of C-S8c1 (33). The capsid proteins VP1, VP2, and VP3 are represented as dark, medium, and light grey, respectively. VP1 from a neighboring protomer is shown at
the upper right. The position of the G-H loop of VP1 in C-S8c1 corresponding to that found in the complex with MAb SD6 is shown in light grey at the center of each
structure (27). The substituted residues are depicted in van der Waals spheres. The amino acids indicated are those listed in Table 5 for MARLS and R100. The minimal
side chain-side chain distances measured between critical amino acid residues of MARLS and were 3.6 Å between VP2 D-130 (Cd2) and VP1 A-145 (N), 4.5 Å between
VP3 K-173 (Nz) and VP1 Q-200 (Oε1), 4.7 Å between VP3 K-173 (Cd) and VP1 R-141 (Nε), 5.1 Å between VP1 Q-200 (Ca) and VP1 R-141 (Cz), 12.7 Å between VP1
R-197 (Ca) and VP1 R-141 (Nh2), and 15.0 Å between VP3 S-178 (Cb) and VP1 P-156 (Cg). The corresponding Ca-Ca distances were 6.8, 5.6, 9.5, 9.7, 17.9, and 16.5
Å, respectively. A minimal side chain distance of 13.3 Å was measured between R100 VP1 D-194 (Od2) and VP1 R-141 (Nh2). The corresponding Ca-Ca distance was
21.1 Å. The origin of the viruses and the procedures used to locate amino acids on the capsid structure are described in Materials and Methods.
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MARLS capsid, and clones derived from C-S8c1 p100 [Table
3]), an enhanced affinity for heparin correlated with the inhi-
bition of infectivity by soluble heparin and with the ability to
infect CHO cells. However, in contrast to FMDV of serotype
O, the presence of cell surface HS was dispensable for infec-
tion of CHO cells, since these tissue culture-adapted C-S8c1
variants replicate in CHO mutant derivatives pgsA-745 and
pgsD-677, which are deficient in GAG biosynthesis (22, 34). In
assays carried out in parallel with the same cells at the same
passage number, wild-type CHO cells, but not the mutant cells
pgsA-745 and pgsD-677, were infected with FMDV O1K, a re-
sult which agrees with the observations of Jackson et al. (31).
The distinct levels of virulence displayed by FMDV in each cell
line document that the virulence determinants for different cell
lines in culture are not identical. Virulence levels may be in-
fluenced by a number of variables affecting the virus and the
cells (growth rate, cell density at confluency, etc.).
The evolutionary history, which in this case is distinguished
by adaptation of FMDV either to cytolytic infections or to per-
sistent infections, influenced the host range of FMDV. The hy-
pervirulent R100 FMDV mutant, rescued after prolonged per-
sistence in BHK-21 cells, was unable to replicate in CHO cells
despite its relative high affinity for heparin. Therefore, the ac-
quisition of heparin-binding capacity does not entail an ability
to infect CHO cells or to use HS as coreceptor. Studies are now
in progress to identify the step in the replication cycle of
FMDV R100 that is blocked in CHO cells. The results re-
ported here suggest that adaptation of FMDV to cell culture
involves multiple virulence determinants. The acquisition of
elevated virulence during persistent infections clearly depends
on mechanisms other than those operating during cytolytic
passages.
Biological selection in vitro was exploited to identify the
amino acid residues associated with binding of MARLS to hep-
arin. Reversion of the heparin-binding phenotype of MARLS
was accompanied by two substitutions, Lys-1733Met in VP3
and Ser-144 3 Leu in the G-H loop of VP1. Interestingly,
these mutations abolished the replication of the virus in wild-
type and mutant CHO cells. Lys-173 of VP3 was present in all
FMDV variants with cytolytic passage histories in BHK-21 cell
cultures, suggesting that this positively charged amino acid
played a central role in the interaction of the virus with hep-
arin. In contrast, the presence of the Ser-144 in VP1 was not
required for binding to heparin. Positioning of the critical res-
idues in the three-dimensional structure of C-S8c1 (33) indi-
cated that Lys-173 of VP3 was one of a cluster of amino acid
replacements surrounding the G-H loop of VP1 (Fig. 4). These
replacements may also affect integrin recognition by FMDV,
since viable mutants with substitutions within the RGD triplet
were selected from C-S8c1 p100—a population which included
the cluster of replacements on VP1 and VP3—but not from
C-S8c1 (37). However, only Asp-130 of VP2, which is present
in MARLS but not in C-S8c1p100 or C-S8c1p100c10 (Table 5),
could potentially form a hydrogen bond with the main chain of
Ala-145 in VP1, assuming that the position of the G-H loop of
VP1 is that recently defined in a complex with MAb SD6 (27).
The distances measured between the sites of other capsid re-
placements and the G-H loop of VP1 preclude a direct inter-
action between the relevant residues. The ability to infect
CHO cells may therefore be the result of an interaction of the
VP3 Lys-173 and other residues surrounding the G-H loop
with structures (heparin-like or other) present at the cell sur-
face that could act as receptors or coreceptors for FMDV on
these cells. Because of the likely hinge movement of the G-H
loop of VP1 (27, 35), it cannot be excluded that certain loop
positions could bring into contact some loop residues with
those found substituted in the variant FMDVs. This possibility
is currently under investigation.
Some of the evidence presented here suggests that the pro-
truding, mobile G-H loop of VP1 may exert some influence in
the interaction with heparin. First, all four MARLS/hs2 mu-
tant clones included Ser-144 3 Leu substitutions in the loop
(Table 5). It cannot be totally excluded that Ser-144 conferred
some selective disadvantage to FMDV during the process
of negative selection for heparin binding for reasons unre-
lated to this phenotype. However, this seems unlikely in
view of the high fitness and stability of the MARLS mutant
upon repeated passages in BHK-21 cells (3). Second, mu-
tant C-S8c1p100RGG displayed decreased binding to heparin
compared to mutant C-S8c1p100c10 (Table 3). The capsids of
these two viruses differ only in the presence of a Gly residue
instead of an Asp in the RGG variant. Additional selection
experiments for FMDV mutants with decreased affinity for
heparin are in progress to determine whether mutations af-
fecting the G-H loop of VP1 may influence heparin binding. It
is noteworthy that the capsid residues which affect heparin
binding in the populations derived from clone C-S8c1 are lo-
cated at completely different positions than the relevant resi-
dues identified for FMDV serotype O (51). This means either
that a variety of different capsid modifications may lead to the
same heparin-binding phenotype or that different FMDV se-
rotypes require different capsid modifications to achieve the
same phenotypic result. This would not be the only biologically
relevant difference among FMDV serotypes. We have recently
documented the critical participation of the Asp-143 residue of
the Arg-Gly-Asp triplet in the binding of neutralizing antibod-
ies directed to the major antigenic site A (located within the
G-H loop of VP1) of serotype C FMDV (57–59). This critical
participation of the Arg-Gly-Asp triplet in antibody binding
does not seem to apply to FMDV of serotype A (40, 45). This
illustrates how evolution may drive individual representatives
of a single viral genus to adopt different biological solutions for
similar processes.
Although the observations on the use of integrin and HS
receptors by FMDV have involved studies in cell cultures, it is
by no means unlikely that changes in cell tropism could play a
role in the infection process of FMDV in vivo. Sequestration of
virus to particular cell types (esopharyngeal region during per-
sistence or stratum spinosum of the vascular dermis during
formation of the typical vesicles [reviewed in reference 17])
may depend on very few amino acid substitutions in capsid
amino acid residues. Mutants with few substitutions relative to
a dominant genomic sequence are likely to occur within the
range of genomic fluctuations in quasispecies mutant spectra
(11). The elucidation of possible variations of cell tropism in
vivo poses an important challenge in view of the ample an-
tigenic diversity of FMDV even within serotype C (42). The
amino acid substitutions responsible for the antigenic differ-
ences may also exert some effect on the recognition of different
cell types.
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